Farxiga

This page shows the latest Farxiga news and features for those working in and with pharma, biotech and healthcare.

FDA advisors say no to empagliflozin in type 1 diabetes

Meanwhile, in July the FDA also turned down AstraZeneca’s filing for its SGLT2 drug Farxiga (dapagliflozin) in type 1 diabetes, although the drug has been approved in this indication in

Latest news

AZ reports growth again in Q3, driven by oncology and China sales

Its cardiovascular, renal and metabolism (CVRM) franchise was also up 11% to $1.1bn, with growth in sales of Brilinta and Farxiga paving the way. ... Tagrisso, Imfinzi and PT010 also had positive data, and we delivered breakthrough data in heart failure
AZ’s Farxiga gets heart failure prevention okay from FDA

AstraZeneca’s Farxiga has become the first drug in the SGLT2 inhibitor class to be approved in the US to reduce the chances of hospitalisations for heart failure in adults with ... Farxiga is also under regulatory review in China to reduce
Novartis grows in Q3 thanks to stellar performance of key drugs

Novartis has also been facing increasing competition in this therapy area, from the likes of Eli Lilly/Boehringer Ingelheim’s Jardiance and AstraZeneca’s Farxiga.
J&J’s Invokana gets lifeline with new kidney disease approval

Farxiga brought in $1.4bn in sales for AZ last year, just over half the $2.7bn made by Jardiance. ... Farxiga and Jardiance could both get another boost from new data showing they can reduce heart failure in both diabetic and non-diabetic patients.
FDA fast-tracks AstraZeneca’s Farxiga in heart failure

This study investigated Farxiga in heart failure patients with reduced ejection fraction (HFrEF). ... to explore Farxiga as a potential new treatment option for heart failure patients,” he added.

More from news
Approximately 10 fully matching, plus 30 partially matching documents found.

Latest Intelligence

China: AstraZeneca’s new engine for growth and innovation

One of its latest launches in the country is Farxiga, its contender in the SGLT2 inhibitor diabetes market.
Transforming times at AstraZeneca

and was the pharma company with the most approvals from the US FDA with four last year, including the diabetes drug Farxiga (dapagliflozin) and Lynparza (olaparib) for ovarian cancer.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Account Executive: Salary TBC

Graduate Scientific Editor: DOE

Senior Medical Writer: Salary TBC

Editorial Team Leader – Medical Communications – Buckinghamshire...: Salary TBC

Account Supervisor: Salary TBC

Senior Editor - Medical Communications - South East - Buckingham...: Highly competitive salary &package

Medical Writer – Very Flexible Working – Surrey: Negotiable

Entry Level Editorial Assistant – Medical Education –Buckinghams...: Highly Competitive

Account Director, Medical Education: Salary TBC

Account Director: Salary TBC

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Scientific Director - Medical Communications - Berkshire: Excellent package on offer

Subscribe to our email news alerts

PMHub

Add my company

Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

RWE Blog 3: Is real-world evidence the holy grail: We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...
What do Healthcare Professionals think about the inclusion of remote selling techniques?: Evolving to a digitally focused pharma / healthcare company - an organisational roadmap...
Strengthening business competition and reducing anti-competitive practices: How the CMA is tackling high prices for essential drugs...